ES487923A0 - Un procedimiento para la preparacion de espiro-quinolilludantoinas, utiles como inhibidores de la aldosa-reductasa para el tratamiento de las complicaciones cronicas de la diabetes - Google Patents

Un procedimiento para la preparacion de espiro-quinolilludantoinas, utiles como inhibidores de la aldosa-reductasa para el tratamiento de las complicaciones cronicas de la diabetes

Info

Publication number
ES487923A0
ES487923A0 ES487923A ES487923A ES487923A0 ES 487923 A0 ES487923 A0 ES 487923A0 ES 487923 A ES487923 A ES 487923A ES 487923 A ES487923 A ES 487923A ES 487923 A0 ES487923 A0 ES 487923A0
Authority
ES
Spain
Prior art keywords
quinolilludantoins
aldosa
spiro
diabetes
procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES487923A
Other languages
English (en)
Other versions
ES8103090A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of ES8103090A1 publication Critical patent/ES8103090A1/es
Publication of ES487923A0 publication Critical patent/ES487923A0/es
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
ES487923A 1979-01-22 1980-01-22 Un procedimiento para la preparacion de espiro-quinolilludantoinas, utiles como inhibidores de la aldosa-reductasa para el tratamiento de las complicaciones cronicas de la diabetes Granted ES487923A0 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/005,278 US4176185A (en) 1979-01-22 1979-01-22 Spiro-quinolylhydantoins

Publications (2)

Publication Number Publication Date
ES8103090A1 ES8103090A1 (es) 1981-02-16
ES487923A0 true ES487923A0 (es) 1981-02-16

Family

ID=21715098

Family Applications (1)

Application Number Title Priority Date Filing Date
ES487923A Granted ES487923A0 (es) 1979-01-22 1980-01-22 Un procedimiento para la preparacion de espiro-quinolilludantoinas, utiles como inhibidores de la aldosa-reductasa para el tratamiento de las complicaciones cronicas de la diabetes

Country Status (22)

Country Link
US (1) US4176185A (es)
EP (1) EP0014079B1 (es)
JP (1) JPS5840959B2 (es)
KR (1) KR830001940A (es)
AR (1) AR222685A1 (es)
AT (1) AT365588B (es)
AU (1) AU514271B2 (es)
CA (1) CA1140928A (es)
DE (1) DE3060079D1 (es)
DK (1) DK156399C (es)
EG (1) EG15085A (es)
ES (1) ES487923A0 (es)
FI (1) FI69308C (es)
GR (1) GR72408B (es)
IE (1) IE49365B1 (es)
IL (1) IL59177A (es)
NO (1) NO152172C (es)
NZ (1) NZ192650A (es)
PH (1) PH15472A (es)
PT (1) PT70716A (es)
YU (1) YU41692B (es)
ZA (1) ZA80344B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4176185A (en) * 1979-01-22 1979-11-27 Pfizer Inc. Spiro-quinolylhydantoins
US4490381A (en) * 1979-11-13 1984-12-25 Imperial Chemical Industries Plc 1'-Substituted spiro[imidazolidine-4,3'-indoline]2,2',5-triones
US4248882A (en) * 1980-02-12 1981-02-03 Pfizer Inc. Treating diabetes-associated complications with hydantoin amines
JPS5745185A (en) * 1980-07-21 1982-03-13 Eisai Co Ltd Hydantoin derivative and its preparation
DE3261684D1 (en) * 1981-05-12 1985-02-07 Ici Plc Pyrrole derivatives
WO1989001775A1 (en) * 1987-09-04 1989-03-09 Pfizer Inc. Azolidinedione derivatives
US5068333A (en) * 1990-03-07 1991-11-26 Pfizer Inc. 6-chloro-3,4-dihydro-pyrano [2,3-b]pyridines having the R configuration

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1135915B (de) * 1961-06-29 1962-09-06 Asta Werke Ag Chem Fab Verfahren zur Herstellung neuer, antikonvulsiv wirksamer Spirohydantoine
US3876659A (en) * 1970-09-18 1975-04-08 Sandoz Ag Spiro tricyclic isoindolines
US4117230A (en) * 1976-10-18 1978-09-26 Pfizer Inc. Hydantoin derivatives as therapeutic agents
US4176185A (en) * 1979-01-22 1979-11-27 Pfizer Inc. Spiro-quinolylhydantoins

Also Published As

Publication number Publication date
IE49365B1 (en) 1985-09-18
DK156399B (da) 1989-08-14
NO152172C (no) 1985-08-14
ZA80344B (en) 1981-02-25
AR222685A1 (es) 1981-06-15
PH15472A (en) 1983-01-24
EP0014079B1 (en) 1981-11-18
AT365588B (de) 1982-01-25
JPS5840959B2 (ja) 1983-09-08
DE3060079D1 (en) 1982-01-21
EG15085A (en) 1986-12-30
DK24280A (da) 1980-07-23
FI69308B (fi) 1985-09-30
IL59177A (en) 1982-11-30
KR830001940A (ko) 1983-05-19
IE800109L (en) 1980-07-22
PT70716A (en) 1980-02-01
FI800163A7 (fi) 1980-07-23
FI69308C (fi) 1986-01-10
CA1140928A (en) 1983-02-08
YU13180A (en) 1983-01-21
US4176185A (en) 1979-11-27
NO794318L (no) 1980-07-23
AU5476680A (en) 1980-07-31
NZ192650A (en) 1984-04-27
AU514271B2 (en) 1981-01-29
ATA26780A (de) 1981-06-15
DK156399C (da) 1990-01-08
ES8103090A1 (es) 1981-02-16
JPS55108873A (en) 1980-08-21
IL59177A0 (en) 1980-05-30
GR72408B (es) 1983-11-02
NO152172B (no) 1985-05-06
EP0014079A1 (en) 1980-08-06
YU41692B (en) 1987-12-31

Similar Documents

Publication Publication Date Title
MX5222E (es) Procedimiento para el tratamiento de lactosuero
BR7805735A (pt) Composicao para tratamento de superficies
AR219531A1 (es) Procedimiento para preparar el isomero dextrogiro de un compuesto de espirohidantoina asimetrica
ES498617A0 (es) Procedimiento de preparar complejos cristalinos de inclusion,hormonalmente activos, para el crecimiento de las plantas.
ES493812A0 (es) Procedimiento para el tratamiento de azufre insoluble.
AR211568A1 (es) Un metodo para preparar una composicion para el tratamiento de quemaduras
AR221251A1 (es) Un procedimiento para la preparacion de derivados de 4-piperidino-6,7-dialcoxi-quinazolina
MX157191A (es) Procedimiento para el tratamiento de aceites usados
ES485168A0 (es) Un procedimiento para la preparacion de una composicion far-maceutica util para el tratamiento de la hipercolesteremia.
AR219561A1 (es) Procedimiento para la preparacion de nuevos derivados de 1-piperidino-6,7-dialcoxi-ftalazina utiles como agentes terapeuticos
AR225666A1 (es) Procedimiento para la produccion de derivados para la produccion de derivados de 1-alquil-1-alquenil,alcoxi o alquil-3-5-alquil,fenil o halo-3-isoxazolilourea
MX6053E (es) Procedimiento microbiologico para la preparacion de derivados del sesquiterpeno
MX148557A (es) Mejoras en metodo para el tratamiento de la madera
MX3635E (es) Procedimiento para la produccion de compuestos de 3-aciloximetilcefem
AR231536A1 (es) Procedimiento para la elaboracion de derivados del acido 5-o 6-alcanoil-,5-o 6-cicloalcanoil- y 5-o 6-benzoil-benzimidazol-2-carboxilico
DOP1977002589A (es) Procedimiento para la preparacion de nuevas tiazolinas.
ES507758A0 (es) Un procedimiento para la preparacion de nuevos derivados de quinoleinetanol o quinoleinpropanol utiles como medicamentos
AR226532A1 (es) Procedimiento para la preparacion de azocompuestos
AR220548A1 (es) Procedimiento para la preparacion de una heterovacuna para el tratamiento terapeutico del sindrome de trichomonas
MX146414A (es) Mejoras en maquina para el tratamiento de esparragos
AR219314A1 (es) Procedimiento para la produccion de piensos
MX5554E (es) Metodo para el cultivo de basidiomecetes
AR218937A1 (es) Metodo para el tratamiento de acido fosforico
AR212999A1 (es) Proceso para la preparacion de di-n-propil acetonitrilo
AR220127A1 (es) Procedimiento para la preparacion de d-homopregna-4,8-dieno-3,20-dionas

Legal Events

Date Code Title Description
MM4A Patent lapsed

Effective date: 19960401